Fatty Liver Disease Equipment In USA
-
Manufactured by Altimmune Inc.based in USA
A peptide-based dual GLP-1/glucagon receptor agonist designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis (NASH). NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD), involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid ...
-
Manufactured by G3T Therapeuticsbased in USA
All drugs targeting cardiovascular disease currently on the market work by lowering cholesterol levels. G3T identified and genetically validated an entirely novel biological mechanism and potential drug target that treats both cardiovascular disease, as well as non-alcoholic fatty liver disease. This is an ...
-
Manufactured by InSphero AGbased in SWITZERLAND
The 3D InSight™ Steatosis Model is an advanced human disease model that enables you to screen compounds and investigate disease pathophysiology using a physiologically relevant human liver microtissue that recapitulates the first stage of non-alcoholic fatty liver disease: ...
-
Manufactured by Quansys Biosciences Inc.based in USA
in bone marrow. Decreased adiponectin levels are associated with metabolic disorders, including non-alcoholic fatty liver disease, obesity, type 2 diabetes, insulin resistance, and atherosclerosis, as well as some cancers. Studies suggest that the hormone promotes the synthesis of HDL cholesterol and low levels of adiponectin are associated with ...
-
Manufactured by InSphero AGbased in SWITZERLAND
inflammation and fibrosis. Ideal for investigating mechanisms of non-alcoholic steatohepatitis (NASH) induction, in vitro screening of anti-NASH drug efficacy, and safety assessment of drug candidates in a relevant disease background, this powerful model includes all the critical liver cells and inducers needed to recapitulate the progression of human ...
-
by CohBar, Inc.based in USA
. Has been shown in a clinical study to significantly reduce ALT and AST, key biomarkers of liver damage, as well as glucose levels compared to placebo. Resulted in a trend towards lower body weight compared to placebo in a clinical ...
-
based in USA
Glycotest blood tests are being developed to provide information on the likelihood of serious liver disease like cancer or fibrosis-cirrhosis by employing technology designed to measure two kinds of disease signals: The amount of the monosaccharide fucose that appears abnormally on certain serum glycoproteins—to indicate ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you